Havtop 50 Tablet contains Topiramate 50mg, an antiepileptic agent used primarily for the management of epilepsy and prevention of migraine headaches. Topiramate acts by stabilizing neuronal membranes and enhancing gamma-aminobutyric acid (GABA) activity, thereby reducing the frequency and severity of seizures. It is indicated for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in adults and pediatric patients. Additionally, Havtop 50 is prescribed for migraine prophylaxis in patients experiencing frequent or disabling migraine attacks. The medication is typically administered orally, with dosing individualized based on clinical response and tolerability. Common adverse effects include dizziness, fatigue, paresthesia, cognitive disturbances, and weight loss. Caution is advised in patients with a history of kidney stones, metabolic acidosis, or glaucoma, as Topiramate may exacerbate these conditions. It is contraindicated in individuals with known hypersensitivity to the drug. Regular monitoring of renal function and serum bicarbonate levels is recommended during prolonged therapy. Patients should be counseled on the importance of adherence and informed about potential side effects. Havtop 50 Tablet should be used under strict medical supervision to optimize therapeutic outcomes and minimize risks.